Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Running, not enrolling · Phase 3

Conditions studied: Treatment Resistant Depression

In brief

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Key facts

Study ID
NCT05711940
Run by
COMPASS Pathways
People needed
572
Starts
2023-02-14
Expected to finish
2026-12-01
Last updated by the study team
2026-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.